This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Miransertib
- DrugBank Accession Number
- DB14982
- Background
Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Miransertib (DB14982)
- Weight
- Average: 432.531
Monoisotopic: 432.206244797 - Chemical Formula
- C27H24N6
- Synonyms
- 3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}pyridin-2-amine
- ARQ 092
- ARQ-092
- ARQ092
- Miransertib
- External IDs
- ARQ 092
- MK 7075
- MK-7075
- MK7075
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- T1DQI1B52Y
- CAS number
- 1313881-70-7
- InChI Key
- HNFMVVHMKGFCMB-UHFFFAOYSA-N
- InChI
- InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)
- IUPAC Name
- 3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}pyridin-2-amine
- SMILES
- NC1=NC=CC=C1C1=NC2=CC=C(N=C2N1C1=CC=C(C=C1)C1(N)CCC1)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 57251282
- ChEMBL
- CHEMBL4297188
- ZINC
- ZINC000072315647
- PDBe Ligand
- 6S1
- PDB Entries
- 5kcv
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) 1 2 Recruiting Treatment Proteus Syndrome 1 1 Completed Other Proteus Syndrome 1 1 Completed Treatment Lymphoma / Solid Tumors / Tumor 1 1 Terminated Treatment Endometrial Cancer / Ovarian Cancer / Solid Tumors 1 1, 2 Terminated Treatment PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) 1 Not Available No Longer Available Not Available Growth Disorders / PIK3CA-Related Overgrowth Spectrum (PROS) / Proteus Syndrome 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00313 mg/mL ALOGPS logP 4.66 ALOGPS logP 4.86 Chemaxon logS -5.1 ALOGPS pKa (Strongest Basic) 9.65 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 95.64 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 150.66 m3·mol-1 Chemaxon Polarizability 48.66 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:39 / Updated at July 18, 2023 22:57